Efficacy and Safety of Adalimumab and Infliximab for Noninfectious Uveitis

Felicia Tai; Parsa Mehraban Far; Petros Pechlivanoglou; Lauren C Ramsay; Jorge R Georgakopoulos; Beate Sander; Larissa A Derzko-Dzulynsky; Tina Felfeli

doi:10.1016/j.ophtha.2021.09.025

Efficacy and Safety of Adalimumab and Infliximab for Noninfectious Uveitis

Ophthalmology. 2022 Mar;129(3):357-359. doi: 10.1016/j.ophtha.2021.09.025. Epub 2021 Oct 8.

Authors

Felicia Tai¹, Parsa Mehraban Far², Petros Pechlivanoglou³, Lauren C Ramsay⁴, Jorge R Georgakopoulos⁵, Beate Sander⁶, Larissa A Derzko-Dzulynsky⁷, Tina Felfeli⁸

Affiliations

¹ Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
² Department of Ophthalmology, Kingston Health Sciences Center, Queen's University, Kingston, Canada.
³ Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto, Canada; Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
⁴ Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.
⁵ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada.
⁶ Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada; Public Health Ontario, Toronto, Canada; ICES, Toronto, Canada.
⁷ Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada; Department of Ophthalmology, St. Joseph's Health Centre, Unity Health Toronto, Toronto, Canada; Department of Ophthalmology, St. Michael's Hospital, Unity Health Toronto, Toronto, Canada.
⁸ Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada. Electronic address: tina.felfeli@mail.utoronto.ca.

PMID: 34634363
DOI: 10.1016/j.ophtha.2021.09.025

No abstract available

Keywords: Adalimumab; Anti–tumor necrosis factor; Biologics; Efficacy; Infliximab; Noninfectious Uveitis; Safety; tumour necrosis factor inhibitor.

Publication types

Comparative Study

MeSH terms

Adalimumab / adverse effects
Adalimumab / therapeutic use*
Drug-Related Side Effects and Adverse Reactions / epidemiology
Eye Infections / drug therapy
Humans
Infliximab / adverse effects
Infliximab / therapeutic use*
Treatment Outcome
Tumor Necrosis Factor Inhibitors / adverse effects
Tumor Necrosis Factor Inhibitors / therapeutic use*
Uveitis / drug therapy*
Uveitis / physiopathology
Visual Acuity / physiology

Substances

Tumor Necrosis Factor Inhibitors
Infliximab
Adalimumab